$5.79 Billion is the total value of Avoro Capital Advisors LLC's 46 reported holdings in Q1 2021. The portfolio turnover from Q4 2020 to Q1 2021 was 27.3% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| HZNP | HORIZON THERAPEUTICS PLC | $828,360,000 | +25.8% | 9,000,000 | 0.0% | 14.31% | +26.2% | |
| MRTX | Buy | MIRATI THERAPEUTICS INC | $800,828,000 | -19.6% | 4,675,000 | +3.1% | 13.83% | -19.4% |
| UTHR | Buy | UNITED THERAPEUTICS CORP | $501,810,000 | +16.0% | 3,000,000 | +5.3% | 8.67% | +16.3% |
| XLRN | Buy | ACCELERON PHARMA INC | $406,830,000 | +105.2% | 3,000,000 | +93.5% | 7.03% | +105.7% |
| VRTX | New | VERTEX PHARMACEUTICALS INC | $300,846,000 | – | 1,400,000 | +100.0% | 5.20% | – |
| ARNA | Sell | ARENA PHARMACEUTICALS INC | $281,030,000 | -12.7% | 4,050,000 | -3.3% | 4.85% | -12.5% |
| ARGX | Buy | ARGENX SEsponsored adr | $254,873,000 | -4.0% | 925,500 | +2.5% | 4.40% | -3.7% |
| IOVA | Buy | IOVANCE BIOTHERAPEUTICS INC | $253,280,000 | -27.2% | 8,000,000 | +6.7% | 4.37% | -27.0% |
| New | ASCENDIS PHARMAsponsored adr | $244,872,000 | – | 1,900,000 | +100.0% | 4.23% | – | |
| MDGL | Buy | MADRIGAL PHARMACEUTICALS INC | $166,682,000 | +22.4% | 1,425,000 | +16.3% | 2.88% | +22.8% |
| SRPT | Buy | SAREPTA THERAPEUTICS INC | $160,240,000 | -46.3% | 2,150,000 | +22.9% | 2.77% | -46.1% |
| BMRN | BIOMARIN PHARMACEUTICAL INC | $124,592,000 | -13.9% | 1,650,000 | 0.0% | 2.15% | -13.6% | |
| FOLD | Buy | AMICUS THERAPEUTICS INC | $121,030,000 | -41.8% | 12,250,000 | +36.1% | 2.09% | -41.6% |
| KURA | KURA ONCOLOGY INC | $113,080,000 | -13.4% | 4,000,000 | 0.0% | 1.95% | -13.2% | |
| MRSN | MERSANA THERAPEUTICS INC | $110,024,000 | -39.2% | 6,800,000 | 0.0% | 1.90% | -39.0% | |
| ADVM | ADVERUM BIOTECHNOLOGIES INC | $78,880,000 | -9.0% | 8,000,000 | 0.0% | 1.36% | -8.8% | |
| PMVP | Buy | PMV PHARMACEUTICALS INC | $77,629,000 | -40.5% | 2,360,267 | +0.4% | 1.34% | -40.3% |
| CNST | CONSTELLATION PHARMACEUTICALS INC | $69,001,000 | -18.8% | 2,950,000 | 0.0% | 1.19% | -18.5% | |
| XENE | Buy | XENON PHARMACEUTICALS INC | $65,335,000 | +51.7% | 3,650,000 | +30.4% | 1.13% | +52.0% |
| ACAD | Buy | ACADIA PHARMACEUTICALS INC | $64,500,000 | -38.1% | 2,500,000 | +28.2% | 1.11% | -37.9% |
| Sell | TRILLIUM THERAPEUTICS INC | $61,218,000 | -28.2% | 5,700,000 | -1.7% | 1.06% | -28.0% | |
| SNDX | Buy | SYNDAX PHARMACEUTICALS INC | $55,900,000 | +458.6% | 2,500,000 | +455.6% | 0.96% | +461.0% |
| RLMD | RELMADA THERAPEUTICS INC | $53,695,000 | +9.8% | 1,525,000 | 0.0% | 0.93% | +10.1% | |
| Buy | MARINUS PHARMACEUTICALS INC | $50,078,000 | +27.0% | 3,235,000 | +0.1% | 0.86% | +27.4% | |
| PRAX | Buy | PRAXIS PRECISION MEDICINES INC | $47,441,000 | -31.0% | 1,596,495 | +3.3% | 0.82% | -30.8% |
| CBAY | CYMABAY THERAPEUTICS INC | $46,762,000 | -20.9% | 10,300,000 | 0.0% | 0.81% | -20.6% | |
| ISEE | IVERIC BIO INC | $44,805,000 | -10.6% | 7,250,000 | 0.0% | 0.77% | -10.3% | |
| APLS | New | APELLIS PHARMACEUTICALS INC | $42,910,000 | – | 1,000,000 | +100.0% | 0.74% | – |
| DCPH | Sell | DECIPHERA PHARMACEUTICALS INC | $40,042,000 | -46.0% | 893,000 | -31.3% | 0.69% | -45.9% |
| DSGN | New | DESIGN THERAPEUTICS INC | $39,702,000 | – | 1,468,318 | +100.0% | 0.69% | – |
| AVDL | AVADEL PHARMACEUTICALS PLCsponsored adr | $39,460,000 | +35.3% | 4,365,000 | 0.0% | 0.68% | +35.7% | |
| AMRN | AMARIN CORP PLCsponsored adr | $37,260,000 | +27.0% | 6,000,000 | 0.0% | 0.64% | +27.3% | |
| TVTX | Sell | TRAVERE THERAPEUTICS INC | $31,188,000 | -36.4% | 1,249,000 | -30.6% | 0.54% | -36.2% |
| MNKD | Buy | MANNKIND CORP | $29,400,000 | +168.4% | 7,500,000 | +114.3% | 0.51% | +168.8% |
| OLMA | OLEMA PHARMACEUTICALS INC | $24,599,000 | -31.0% | 876,986 | 0.0% | 0.42% | -30.8% | |
| ADAP | ADAPTIMMUNE THERAPEUTICS PLCsponsored adr | $18,851,000 | -1.5% | 3,550,000 | 0.0% | 0.33% | -1.2% | |
| RLAY | RELAY THERAPEUTICS INC | $17,285,000 | -16.8% | 500,000 | 0.0% | 0.30% | -16.5% | |
| MRUS | New | MERUS N V | $13,892,000 | – | 665,000 | +100.0% | 0.24% | – |
| GNCA | GENOCEA BIOSCIENCES INC | $13,778,000 | +12.0% | 5,084,184 | 0.0% | 0.24% | +12.3% | |
| RNA | AVIDITY BIOSCIENCES INC | $11,886,000 | -14.5% | 545,000 | 0.0% | 0.20% | -14.6% | |
| BDTX | Sell | BLACK DIAMOND THERAPEUTICS INC | $10,674,000 | -48.0% | 440,000 | -31.2% | 0.18% | -47.9% |
| RACA | THERAPEUTICS ACQUISITION CORP | $10,510,000 | -24.7% | 1,000,000 | 0.0% | 0.18% | -24.2% | |
| FENC | FENNEC PHARMACEUTICALS INC | $10,371,000 | -16.6% | 1,670,000 | 0.0% | 0.18% | -16.4% | |
| BCTG | BCTG ACQUISITION CORP | $8,896,000 | -2.8% | 800,000 | 0.0% | 0.15% | -2.5% | |
| JNCE | New | JOUNCE THERAPEUTICS INC | $5,700,000 | – | 555,000 | +100.0% | 0.10% | – |
| GLPG | New | GALAPAGOS NVsponsored adr | $239,000 | – | 3,100 | +100.0% | 0.00% | – |
| NKTR | Exit | NEKTAR THERAPEUTICScall | $0 | – | -100,000 | -100.0% | 0.00% | – |
| ATNX | Exit | ATHENEX INC | $0 | – | -372,500 | -100.0% | -0.07% | – |
| CUE | Exit | CUE BIOPHARMA INC | $0 | – | -452,500 | -100.0% | -0.10% | – |
| ITOS | Exit | ITEOS THERAPEUTICS INC | $0 | – | -460,000 | -100.0% | -0.27% | – |
| ASND | Exit | ASCENDIS PHARMAsponsored adr | $0 | – | -1,800,000 | -100.0% | -5.17% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2021-05-17
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| AMICUS THERAPEUTICS INC | 36 | Q3 2023 | 17.9% |
| MIRATI THERAPEUTICS INC. | 35 | Q3 2023 | 17.2% |
| BIOMARIN PHARMACEUTICAL INC | 31 | Q3 2023 | 8.0% |
| SAREPTA THERAPUTICS INC | 28 | Q3 2023 | 14.8% |
| ASCENDIS PHARMA | 28 | Q3 2023 | 9.1% |
| ARGENX SE | 26 | Q3 2023 | 9.5% |
| IOVANCE BIOTHERAPEUTICS INC | 26 | Q3 2023 | 9.1% |
| FENNEC PHARMACEUTICALS INC | 25 | Q3 2023 | 0.4% |
| MADRIGAL PHARMACEUTICALS INC | 22 | Q3 2023 | 7.2% |
| XENON PHARMACEUTICALS INC | 22 | Q3 2023 | 3.3% |
View Avoro Capital Advisors LLC's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Adverum Biotechnologies, Inc.Sold out | February 14, 2023 | 0 | 0.0% |
| DICE Therapeutics, Inc. | February 14, 2023 | 2,525,555 | 5.3% |
| IOVANCE BIOTHERAPEUTICS, INC. | February 14, 2023 | 7,020,000 | 4.4% |
| IVERIC bio, Inc. | February 14, 2023 | 6,750,000 | 5.0% |
| Kura Oncology, Inc. | February 14, 2023 | 3,105,000 | 4.5% |
| Aadi Bioscience, Inc. | September 26, 2022 | 2,849,402 | 11.7% |
| ARENA PHARMACEUTICALS INC | February 11, 2022 | 1,235,000 | 2.0% |
| AVADEL PHARMACEUTICALS PLC | February 11, 2022 | 1,670,000 | 2.9% |
| FENNEC PHARMACEUTICALS INC. | February 11, 2022 | 1,200,000 | 4.6% |
| POINT Biopharma Global Inc.Sold out | February 11, 2022 | 0 | 0.0% |
View Avoro Capital Advisors LLC's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| SC 13G/A | 2024-04-23 |
| 13F-HR | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
View Avoro Capital Advisors LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.